The Veteran's adenocarcinoma of the prostate gland has been rated at 60 percent since November 1, 2009. The Board found that the residuals do not meet criteria for a higher rating as there is no local recurrence or metastasis and urinary leakage requiring absorbent materials changed more than four times per day.
The deciding factor: The Veteran's prostate cancer has been in remission with no local recurrence or metastasis, and his residuals are manifested by urinary leakage requiring absorbent materials changed more than four times per day. The predominant residual symptom is voiding dysfunction, which warrants a 60 percent rating under Diagnostic Code 7528.
- Claimed conditions
- adenocarcinoma of the prostate gland
- How they argued it
- Direct service connection
- Exposure basis
- None
- Rating
- Not verified here — check the original decision
- Decision date
- May 4, 2018
- Citation
- 18101331
This is a plain-language summary generated by AI from a public Board of Veterans’ Appeals decision. It can contain errors — always verify against the original. Read the original VA decision (opens in a new tab) using citation 18101331.
What this means for you
A final Board denial may be appealed to the U.S. Court of Appeals for Veterans Claims, generally within 120 days of the Board mailing date. A Supplemental Claim with new and relevant evidence is a separate option. Another Higher-Level Review of the Board decision is not available. Check your own notice: this historical decision does not set your deadline.
What you can do next
Use your own notice and decision stage. A remanded issue is not a final court-appealable denial. VA review guidance and CAVC filing instructions (U.S. federal; reviewed October 7, 2026).
Related decisions
Other Board decisions on a similar condition or argued the same way.
- Whole decision: Granted
The Veteran's adenocarcinoma of the prostate gland with erectile dysfunction was active from December 21, 2015 to April 25, 2017 and warrants a 100% rating during this period.
- Whole decision: Granted
The Veteran's claim for nonservice-connected pension benefits was granted on May 14, 2003, due to his diagnosis of adenocarcinoma of the prostate gland. The effective date is set at this time as it aligns with when he first met the criteria for entitlement.
- Whole decision: Granted
The Board finds that the reduction of the rating from 100 percent to 10 percent for service-connected residuals of adenocarcinoma of the prostate gland, effective April 1, 2005, was proper.
- Whole decision: Granted
The veteran was found to have adenocarcinoma of the prostate gland, qualifying for nonservice-connected pension benefits effective December 4, 2004.
Free starter guide for your own claim
Reading this because you were denied or under-rated? Get the plain-English next steps — your appeal options, the deadline that protects you, and how appeals like yours turn out. One email, no spam.
We will only use this to send the guide. No spam, unsubscribe any time. We never sell your information.
We are not the VA. Veterans’ Rights is an independent resource built for veterans. We are not the U.S. Department of Veterans Affairs, not part of the government, and not endorsed by any government agency.
This is general information, not legal advice. For advice about your own situation, talk to a VA-accredited representative — many help for free.